PBM
VRCA icon

Propel Bio Management’s Verrica Pharmaceuticals VRCA Stock Holding History

Propel Bio Management’s Portfolio VRCA Stock Details VRCA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-34,494
Closed -$500K – 23
2024
Q3 		$500K Sell
34,494
-8,000
-19% -$360K 0.29% 19
2024
Q2 		$3.1M Buy
+42,494
New +$3.26M 2.01% 14

Other funds holding VRCA

AC
Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return
CP
Caligan Partners New York $2.13B AUM 758.65% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
BFM
Boothbay Fund Management New York $7.6B AUM 109.3% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
SA
Sovran Advisors San Diego, California $1.34B AUM 21.63% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Propel Bio Management's VRCA Position: Q4 2024 in Review

Propel Bio Management sold out of Verrica Pharmaceuticals (VRCA) in Q4 2024, closing a stake of 34,494 shares — an estimated $500K sold.

Propel Bio Management first reported a position in VRCA in Q2 2024 and held it in 2 quarters. The position peaked at $3.1M in Q2 2024. 81 funds tracked by Wall St. Rank hold VRCA as of Q4 2024.

  • Propel Bio Management reported no remaining Verrica Pharmaceuticals position as of Q4 2024 after selling out during the quarter.
  • Propel Bio Management sold 34,494 Verrica Pharmaceuticals shares in Q4 2024, an estimated $500K.
  • Propel Bio Management first reported a position in Verrica Pharmaceuticals in Q2 2024 and held it in 2 quarters.
  • Propel Bio Management's Verrica Pharmaceuticals position peaked at $3.1M in Q2 2024.
  • 81 funds tracked by Wall St. Rank held Verrica Pharmaceuticals as of Q4 2024.

Based on Propel Bio Management's 13F filing for Q4 2024, filed 14 Feb 2025.